ArticleJournal of medical Internet research2021
Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study.
Article in Journal of medical Internet research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06512792 (Mobile App-Based Remote Management Model for IBD Patients), which is not on this map. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mobile App-Based Remote Management Model for IBD Patients: A Multi-Center Randomized Controlled Study
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Efficacy of polyphenols in adjuvant treating ulcerative colitis: A meta-analysis of randomized controlled trials.Medicine · 2025Pooled it
- Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.Journal of Crohn's & colitis · 2024Pooled it
- Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China.Frontiers in public health · 2021Pooled it
- Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials.Clinical and translational science · 2024Trial
- The impact of family health resources on the economic risk of diseases in rural China: based on a path analysis.BMC public health · 2026Article
- Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn's disease in China.World journal of gastroenterology · 2026Article
- Direct and Indirect Costs per Visit for Elderly Patients and Their Caretakers Receiving Complete Dentures in Health Region 9, Thailand.Health services insights · 2026Article
- Flourishing and its influencing factor in inflammatory bowel disease patients: a latent profile analysis.Frontiers in psychiatry · 2026Article
- Gegen Qinlian Decoction, a classic traditional Chinese medicine formula: a potential therapeutic strategy for ulcerative colitis and colorectal cancer.Frontiers in pharmacology · 2026Review
- Global Trends and Future Projections in the Burden of Inflammatory Bowel Disease Among Adolescents and Young Adults (15-49 Years) From 1990 to 2021.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- DeepGut: A collaborative multimodal large language model framework for digestive disease assisted diagnosis and treatment.World journal of gastroenterology · 2025Observational
- Home-based enteral nutrition self-management challenges in young and middle-aged patients with Crohn's disease: a qualitative study.BMJ open · 2025Article
- Fear of progression profiles and their association with quality of life and depression in ischemic stroke survivors: a latent profile analysis.BMC psychiatry · 2025Article
- Social alienation in patients with inflammatory bowel diseases: A latent profile analysis.International journal of nursing sciences · 2025Article
- Care needs profiles of Crohn's disease patients and their associations with symptom clusters, post-traumatic growth, and family function: a latent profile analysis.BMC gastroenterology · 2025Article
- Global and Chinese Burden of Inflammatory Bowel Disease From 1990 to 2021: A Systematic Analysis and Prediction of Disease Burden.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- The impact of a PERMA model-based positive psychology intervention on fear of recurrence of inflammatory bowel disease: a randomized controlled trial.Frontiers in psychology · 2025Article
- The Construction Strategy of Curcumin Nanomedicine Delivery System and Its Application in the Treatment of Ulcerative Colitis.International journal of nanomedicine · 2025Review
- Factors Influencing Decision-Making Preferences Among Patients with Inflammatory Bowel Disease: A Cross-Sectional Study in China.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing incidence of inflammatory bowel disease (IBD) has imposed heavy financial burdens for Chinese patients; however, data about their financial status and access to health care are still lacking. This information is important for informing patients with IBD about disease treatment budgets and health care strategies.
objectiveThe aim of this study was to evaluate the economic status and medical care access of patients with IBD through the China Crohn's & Colitis Foundation web-based platform in China.
methodsOur study was performed in 14 IBD centers in mainland China between 2018 and 2019 through WeChat. Participants were asked to complete a 64-item web-based questionnaire. Data were collected by the Wenjuanxing survey program. We mainly focused on income and insurance status, medical costs, and access to health care providers. Respondents were stratified by income and the associations of income with medical costs and emergency visit times were analyzed.
resultsIn this study, 3000 patients with IBD, that is, 1922 patients with Crohn disease, 973 patients with ulcerative colitis, and 105 patients with undetermined colitis were included. During the last 12 months, the mean (SD) direct and indirect costs for per patient with IBD were approximately US $11,668.68 ($7944.44) and US $74.90 ($253.60) in China. The average reimbursement ratios for most outpatient and inpatient costs were less than 50%. However, the income of 85.5% (2565/3000) of the patients was less than ¥10,000 (US $1445) per month. Approximately 96.5% (2894/3000) of the patients were covered by health insurance, but only 24.7% (741/3000) of the patients had private commercial insurance, which has higher imbursement ratios. Nearly 98.0% (2954/3000) of the patients worried about their financial situation. Thus, 79.7% (2392/3000) of the patients with IBD tried to save money for health care and even delayed their medical treatments. About half of the respondents (1282/3000, 42.7%) had no primary care provider, and 52.2% (1567/3000) of the patients had to visit the emergency room 1-4 times per year for the treatment of their IBD. Multivariate analysis revealed that lower income (P=.001) and higher transportation (P=.004) and accommodation costs (P=.001) were significantly associated with the increased number of emergency visits of the patients.
conclusionsChinese patients with IBD have enormous financial burdens and difficulties in accessing health care, which have increased their financial anxiety and inevitably influenced their disease outcomes. Early purchase of private insurance, thereby increasing the reimbursement ratio for medical expenses, and developing the use of telemedicine would be effective strategies for saving on health care costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.